Patent intelligence · WO
WO 03105839
VERWENDUNG VON RIBAVIRIN ZUR HERSTELLUNG EINER PHARMAZEUTISCHEN ZUSAMMENSETZUNG GEGEN BUNYAVIRIDAE
VERWENDUNG VON RIBAVIRIN ZUR HERSTELLUNG EINER PHARMAZEUTISCHEN ZUSAMMENSETZUNG GEGEN BUNYAVIRIDAE
Patent details — WO 03105839
- Jurisdiction
- WO
- Status
- expired
- Grant date
- Dec 24, 2003
- Expiration
- Dec 19, 2023
- Applicant
- BIOPARTNERS GMBH [CH]
- CPC classes
- A61K 31/ 41 A I, A61K/3141, A61K31/41
Quick answer
WO 03105839 (VERWENDUNG VON RIBAVIRIN ZUR HERSTELLUNG EINER PHARMAZEUTISCHEN ZUSAMMENSETZUNG GEGEN BUNYAVIRIDAE) is held by BIOPARTNERS GMBH [CH]. Status: expired. Granted Dec 24, 2003. Expires Dec 19, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOPARTNERS GMBH [CH]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 41 A I, A61K/3141, A61K31/41
More from BIOPARTNERS GMBH [CH]
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 03105839?
WO 03105839 (VERWENDUNG VON RIBAVIRIN ZUR HERSTELLUNG EINER PHARMAZEUTISCHEN ZUSAMMENSETZUNG GEGEN BUNYAVIRIDAE) is held by BIOPARTNERS GMBH [CH]. Status: expired. Granted Dec 24, 2003. Expires Dec 19, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 03105839?
BIOPARTNERS GMBH [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does WO 03105839 expire?
Our index shows an expiration date of Dec 19, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.